Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.

19 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

Poniard Pharmaceuticals, Inc. today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Phase III randomized clinical trial for Alpharadin to be commenced

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.

18 Nov 2009

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

Bavarian Nordic A/S announced today that BARDA (Biomedical Advanced Research and Development Authority) has awarded a new contract to Bavarian Nordic for the development of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40 million.

17 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.

17 Nov 2009

Trustmark Voluntary Benefit Solutions offers coverage for vaccines including H1N1 to its policyholders

Trustmark Voluntary Benefit Solutions, a leading provider of payroll-deducted voluntary benefits, is now covering vaccines including H1N1 (swine flu).

17 Nov 2009

Talend bags orders from several global healthcare customers

Talend, the recognized market leader in open source data integration software, today announced several global healthcare customer wins including Children’s Hospital & Medical Center of Omaha, Hosta, The Clermont-Ferrand Hospital and The University for Health Sciences, Medical Informatics and Technology (UMIT). The traction gained in this space further validates Talend’s ability to provide scalable and flexible solutions at an affordable cost to healthcare organizations of all sizes, while satisfying the need for the real-time data the industry demands.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

First-quarter fiscal 2010 results announced by IsoRay

IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009.

16 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Inovio Biomedical Corporation today reported financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Just one test not enough to detect heart defects in young athletes

To best detect early signs of life-threatening heart defects in young athletes, screening programs should include both popular diagnostic tests, not just one of them, according to new research from heart experts at Johns Hopkins.

16 Nov 2009

El Camino Hospital moves into new, technologically and seismically advanced facility

El Camino Hospital, the hospital of Silicon Valley, today completed its move into the new, technologically and seismically advanced facility. After completing several practice runs led by the activation team, hospital officials report all patients were safely transferred to the new facility.

16 Nov 2009

Veterans' health: Measuring the scope of mental health challenges

NPR profiles retired General Eric Shinseki, the head of the Department of Veterans Affairs, and his efforts to measure the scope of veterans' mental health issues. In his first nine months in this position, he "has spent hours just listening to veterans talk. Shinseki tells NPR's Steve Inskeep that he feels a strong obligation to 'give back' to the men and women he once served with." NPR reports on the task Shinseki faces: "Since 2001, more than 1 million new veterans have come into a system that is being stretched thin." One of Shinseki's missions to improve the care and resources available to these vets is to work with the Department of Defense to "create a computer-driven system that will track service personnel through their careers — including when they become veterans.

13 Nov 2009

Third quarter 2009 financial results announced by Soligenix

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009.

13 Nov 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

NeoPharm presents LE-DT Phase I data at the AACR conference

Phase III randomized clinical trial for Alpharadin to be commenced

Bavarian Nordic awarded a new contract for developing a freeze-dried version of its IMVAMUNE smallpox vaccine

Recent developments at Burnham Institute for Medical Research

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

Trustmark Voluntary Benefit Solutions offers coverage for vaccines including H1N1 to its policyholders

Talend bags orders from several global healthcare customers

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

First-quarter fiscal 2010 results announced by IsoRay

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Just one test not enough to detect heart defects in young athletes

El Camino Hospital moves into new, technologically and seismically advanced facility

Veterans' health: Measuring the scope of mental health challenges

Third quarter 2009 financial results announced by Soligenix

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Evolving spectrophotometry for modern biopharma workflows

Newsletters you may be interested in